Viracta Therapeutics, Inc.
4 clinical trials · Sponsor
◉ Watch Viracta Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers (NCT06302140) | Viracta Therapeutics, Inc. | 2024-02-28 |
| Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC (NCT05166577) | Viracta Therapeutics, Inc. | 2021-10-08 |
| An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas (NCT05011058) | Viracta Therapeutics, Inc. | 2021-05-28 |
| Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies (NCT03397706) | Viracta Therapeutics, Inc. | 2018-03-29 |
Track Viracta Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.